Common reported side effects are typically mild: injection site reactions, temporary nausea, or headaches
The approach depends on the severity of deficiency, underlying cause, and presence of neurological symptoms
(2016) conducted a targeted metabolomic analysis to investigate metabolic abnormalities in male participants, including 20 healthy controls (HC), 20 individuals with GWS (diagnosed using both Kansas and CDC criteria), and 22 ME/CFS patients from a previous cohort diagnosed with 2015 Institute of Medicine, CCC, and CDC-1994 diagnostic criteria
In non-clinical laboratory research, this peptide may be applied in receptor binding assays, cell-based signaling studies, ligand interaction experiments, and controlled protocols designed to evaluate peptide behavior